Adaptive Biotechnologies posted an impressive 36% year-over-year revenue increase in Q2 2025, largely fueled by strong demand for its minimal residual disease (MRD) testing business. The MRD segment accounted for 85% of revenues, with clinical and pharma sectors contributing significantly. The firm's ClonoSeq test saw a 57% growth in clinical revenues, supported by expanded reimbursement and increased test volumes. Adaptive improved its net loss compared to the prior year, while maintaining robust pharma milestone gains, positioning it favorably in the diagnostics and immune medicine markets.